Precision Optics (POCI) Investor presentation summary
Event summary combining transcript, slides, and related documents.
Investor presentation summary
16 Apr, 2026Business overview and strategy
Vertically integrated optics company leveraging proprietary micro-optics and imaging technologies for healthcare and defense/aerospace sectors, offering services from concept to mass manufacture.
Over 40 years of growth, with expansion into medical devices, defense, telecom, and recent acquisitions to broaden capabilities.
Business model emphasizes early-stage collaboration with key clients, robust R&D pipeline, and maintaining IP through internal and customer-funded research.
Focus on micro-optics, 3D imaging, and digital imaging, with a disciplined investment approach and facility expansion to support growth.
Strategic acquisitions and the launch of the Unity Platform aim to accelerate development and commercialization of new products.
Key technologies and markets
Specializes in millimeter-sized cameras and patented opto-mechanical/electronic systems for minimally invasive surgery and defense applications.
One of few global providers of 3D endoscopes, supporting next-gen robotic surgery and advanced imaging systems.
Expertise in digital imaging electronics, especially CMOS-based systems, with full system design capabilities for both single-use and reusable devices.
Main markets include medical devices (e.g., neurosurgery, cardiology, urology, arthroscopy) and aerospace/defense (e.g., UAVs, satellite communications, directed energy weapons).
Financial performance and outlook
Revenue grew from $4.0M in 2017 to $21.0M in 2024, with 2026 guidance of $26M–$28M.
Gross margins have ranged from 24% to 40% over recent years.
Adjusted EBITDA has fluctuated, with recent years showing negative values, but improvements are targeted.
Balance sheet as of 12/31/2025 shows $881K in cash, $4.9M in receivables, $4.3M in inventory, and $9.3M in shareholder equity.
Latest events from Precision Optics
- Record revenue growth offset by margin compression and liquidity risks.POCI
Q2 202617 Feb 2026 - Shareholders will vote on director elections, executive pay, and auditor ratification at the 2025 meeting.POCI
Proxy Filing3 Feb 2026 - Votes will be cast on director elections, executive pay, and auditor ratification at the 2026 meeting.POCI
Proxy Filing2 Feb 2026 - Annual meeting to elect directors, approve executive pay, and ratify auditor, with strong governance.POCI
Proxy Filing2 Feb 2026 - Record engineering revenue and new orders support double-digit growth expectations for FY2025.POCI
Q4 202420 Jan 2026 - Strong product pipeline and new production ramp-ups set the stage for record growth in 2025.POCI
Lytham Partners Fall 2024 Investor Conference19 Jan 2026 - Net loss widened on lower revenue and margin, but growth is expected as new programs scale.POCI
Q1 202514 Jan 2026 - Single-use endoscopes and the Unity platform are fueling rapid growth and production expansion.POCI
Lytham Partners 2025 Industrials & Basic Materials Investor Summit26 Dec 2025 - Production revenue surged 42% sequentially, with Unity Imaging Platform launch fueling optimism.POCI
Q2 202524 Dec 2025